Compare STDN & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STDN | XNCR |
|---|---|---|
| Founded | 2024 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2026 | 2013 |
| Metric | STDN | XNCR |
|---|---|---|
| Price | $11.56 | $29.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 14 |
| Target Price | $17.25 | ★ $41.58 |
| AVG Volume (30 Days) | 265.4K | ★ 1.6M |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | $439.23 | $18.52 |
| Revenue Next Year | $259.21 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $7.05 | $10.38 |
| 52 Week High | $17.34 | $33.60 |
| Indicator | STDN | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 41.28 | 64.64 |
| Support Level | $11.42 | $22.80 |
| Resistance Level | $13.73 | $30.61 |
| Average True Range (ATR) | 0.81 | 1.68 |
| MACD | -0.07 | 0.55 |
| Stochastic Oscillator | 10.06 | 63.20 |
Standard Nuclear Inc is an independent advanced nuclear fuel company. The company designs, engineers, and manufactures advanced nuclear fuels, with a primary focus on TRISO fuel for advanced reactors. Its operations include industrial-scale TRISO fuel manufacturing and the development of fuel for advanced reactors that utilize TRISO fuel. The company operates in a single operating and reportable segment, as it is engaged in a single business activity of TRISO production. It derives revenue from fuel development and services agreements. Geographically, the maximum revenue is generated from the United States.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.